Research ExplorerPublicationsCytokeratin 7 and cytokeratin 20 expression in cancer: A tis...

Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers

Standard

Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. / Dum, David; Menz, Anne; Völkel, Cosima; De Wispelaere, Noémi; Hinsch, Andrea; Gorbokon, Natalia; Lennartz, Maximilian; Luebke, Andreas M; Hube-Magg, Claudia; Kluth, Martina; Fraune, Christoph; Möller, Katharina; Bernreuther, Christian; Lebok, Patrick; Clauditz, Till S; Jacobsen, Frank; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah; Marx, Andreas H; Simon, Ronald; Burandt, Eike; Krech, Till.

In: EXP MOL PATHOL, Vol. 126, 104762, 06.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dum, D, Menz, A, Völkel, C, De Wispelaere, N, Hinsch, A, Gorbokon, N, Lennartz, M, Luebke, AM, Hube-Magg, C, Kluth, M, Fraune, C, Möller, K, Bernreuther, C, Lebok, P, Clauditz, TS, Jacobsen, F, Sauter, G, Uhlig, R, Wilczak, W, Steurer, S, Minner, S, Marx, AH, Simon, R, Burandt, E & Krech, T 2022, 'Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers', EXP MOL PATHOL, vol. 126, 104762. https://doi.org/10.1016/j.yexmp.2022.104762

APA

Dum, D., Menz, A., Völkel, C., De Wispelaere, N., Hinsch, A., Gorbokon, N., Lennartz, M., Luebke, A. M., Hube-Magg, C., Kluth, M., Fraune, C., Möller, K., Bernreuther, C., Lebok, P., Clauditz, T. S., Jacobsen, F., Sauter, G., Uhlig, R., Wilczak, W., ... Krech, T. (2022). Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. EXP MOL PATHOL, 126, [104762]. https://doi.org/10.1016/j.yexmp.2022.104762

Vancouver

Dum D, Menz A, Völkel C, De Wispelaere N, Hinsch A, Gorbokon N et al. Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. EXP MOL PATHOL. 2022 Jun;126. 104762. https://doi.org/10.1016/j.yexmp.2022.104762

Bibtex

@article{f7312a1905ca4b10bd7db78abed05f6e,
title = "Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers",
abstract = "Combined analysis of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is often used for assessing the origin of metastatic cancer. To evaluate the diagnostic utility of CK7 and CK20, tissue microarrays containing 15,424 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. CK7 positivity was seen in 52% (8.7% weak, 5.9% moderate, 37% strong) and CK20 positivity in 23% (5.1% weak, 3.4% moderate, 15% strong) of interpretable tumors. Of 8390 positive tumors, 1181 (14%) showed positivity for CK7 and CK20, 5380 (64%) showed positivity for CK7 alone, and 1829 (22%) showed positivity for CK20 alone. CK20 predominated in gastrointestinal tract, urothelial and Merkel cell carcinomas. CK7 was usually negative in prostate cancer and colorectal cancer. Combined evaluation of CK7/CK20 revealed the best diagnostic utility in CK20 positive tumors, where CK7 negativity is often linked to colorectal origin while CK7 positivity argues for urothelial origin or mucinous ovarian cancer. Associations with unfavorable tumor features were found for cytokeratin 7 loss in breast cancer of no special type, urothelial and renal cell carcinomas, for CK7 overexpression in high-grade serous ovarian and gastric cancer, and for CK20 overexpression in urothelial carcinoma. CK20 loss was linked to MSI in gastric (p = 0.0291) and colorectal adenocarcinoma (p < 0.0001). These analyses provide comprehensive data on the frequency of CK7 and CK20 immunostaining - alone or in combination - in human cancers. These data facilitate interpretation of CK7/CK20 immunostaining in cancers.",
keywords = "Biomarkers, Tumor/metabolism, Carcinoma, Transitional Cell/genetics, Colorectal Neoplasms/genetics, Humans, Intermediate Filament Proteins/genetics, Keratin-20/genetics, Keratin-7/genetics, Keratins/analysis, Male, Urinary Bladder Neoplasms/genetics",
author = "David Dum and Anne Menz and Cosima V{\"o}lkel and {De Wispelaere}, No{\'e}mi and Andrea Hinsch and Natalia Gorbokon and Maximilian Lennartz and Luebke, {Andreas M} and Claudia Hube-Magg and Martina Kluth and Christoph Fraune and Katharina M{\"o}ller and Christian Bernreuther and Patrick Lebok and Clauditz, {Till S} and Frank Jacobsen and Guido Sauter and Ria Uhlig and Waldemar Wilczak and Stefan Steurer and Sarah Minner and Marx, {Andreas H} and Ronald Simon and Eike Burandt and Till Krech",
note = "Copyright {\textcopyright} 2022 The Author(s). Published by Elsevier Inc. All rights reserved.",
year = "2022",
month = jun,
doi = "10.1016/j.yexmp.2022.104762",
language = "English",
volume = "126",
journal = "EXP MOL PATHOL",
issn = "0014-4800",
publisher = "Academic Press Inc.",

}

RIS

TY - JOUR

T1 - Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers

AU - Dum, David

AU - Menz, Anne

AU - Völkel, Cosima

AU - De Wispelaere, Noémi

AU - Hinsch, Andrea

AU - Gorbokon, Natalia

AU - Lennartz, Maximilian

AU - Luebke, Andreas M

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Fraune, Christoph

AU - Möller, Katharina

AU - Bernreuther, Christian

AU - Lebok, Patrick

AU - Clauditz, Till S

AU - Jacobsen, Frank

AU - Sauter, Guido

AU - Uhlig, Ria

AU - Wilczak, Waldemar

AU - Steurer, Stefan

AU - Minner, Sarah

AU - Marx, Andreas H

AU - Simon, Ronald

AU - Burandt, Eike

AU - Krech, Till

N1 - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

PY - 2022/6

Y1 - 2022/6

N2 - Combined analysis of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is often used for assessing the origin of metastatic cancer. To evaluate the diagnostic utility of CK7 and CK20, tissue microarrays containing 15,424 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. CK7 positivity was seen in 52% (8.7% weak, 5.9% moderate, 37% strong) and CK20 positivity in 23% (5.1% weak, 3.4% moderate, 15% strong) of interpretable tumors. Of 8390 positive tumors, 1181 (14%) showed positivity for CK7 and CK20, 5380 (64%) showed positivity for CK7 alone, and 1829 (22%) showed positivity for CK20 alone. CK20 predominated in gastrointestinal tract, urothelial and Merkel cell carcinomas. CK7 was usually negative in prostate cancer and colorectal cancer. Combined evaluation of CK7/CK20 revealed the best diagnostic utility in CK20 positive tumors, where CK7 negativity is often linked to colorectal origin while CK7 positivity argues for urothelial origin or mucinous ovarian cancer. Associations with unfavorable tumor features were found for cytokeratin 7 loss in breast cancer of no special type, urothelial and renal cell carcinomas, for CK7 overexpression in high-grade serous ovarian and gastric cancer, and for CK20 overexpression in urothelial carcinoma. CK20 loss was linked to MSI in gastric (p = 0.0291) and colorectal adenocarcinoma (p < 0.0001). These analyses provide comprehensive data on the frequency of CK7 and CK20 immunostaining - alone or in combination - in human cancers. These data facilitate interpretation of CK7/CK20 immunostaining in cancers.

AB - Combined analysis of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is often used for assessing the origin of metastatic cancer. To evaluate the diagnostic utility of CK7 and CK20, tissue microarrays containing 15,424 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. CK7 positivity was seen in 52% (8.7% weak, 5.9% moderate, 37% strong) and CK20 positivity in 23% (5.1% weak, 3.4% moderate, 15% strong) of interpretable tumors. Of 8390 positive tumors, 1181 (14%) showed positivity for CK7 and CK20, 5380 (64%) showed positivity for CK7 alone, and 1829 (22%) showed positivity for CK20 alone. CK20 predominated in gastrointestinal tract, urothelial and Merkel cell carcinomas. CK7 was usually negative in prostate cancer and colorectal cancer. Combined evaluation of CK7/CK20 revealed the best diagnostic utility in CK20 positive tumors, where CK7 negativity is often linked to colorectal origin while CK7 positivity argues for urothelial origin or mucinous ovarian cancer. Associations with unfavorable tumor features were found for cytokeratin 7 loss in breast cancer of no special type, urothelial and renal cell carcinomas, for CK7 overexpression in high-grade serous ovarian and gastric cancer, and for CK20 overexpression in urothelial carcinoma. CK20 loss was linked to MSI in gastric (p = 0.0291) and colorectal adenocarcinoma (p < 0.0001). These analyses provide comprehensive data on the frequency of CK7 and CK20 immunostaining - alone or in combination - in human cancers. These data facilitate interpretation of CK7/CK20 immunostaining in cancers.

KW - Biomarkers, Tumor/metabolism

KW - Carcinoma, Transitional Cell/genetics

KW - Colorectal Neoplasms/genetics

KW - Humans

KW - Intermediate Filament Proteins/genetics

KW - Keratin-20/genetics

KW - Keratin-7/genetics

KW - Keratins/analysis

KW - Male

KW - Urinary Bladder Neoplasms/genetics

U2 - 10.1016/j.yexmp.2022.104762

DO - 10.1016/j.yexmp.2022.104762

M3 - SCORING: Journal article

C2 - 35390310

VL - 126

JO - EXP MOL PATHOL

JF - EXP MOL PATHOL

SN - 0014-4800

M1 - 104762

ER -